Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year Low – Time to Sell?

Posted by Brian Himes on Sep 10th, 2026

Kailera Therapeutics, Inc. (NASDAQ:KLRA – Get Free Report)’s share price hit a new 52-week low on Thursday . The stock traded as low as $14.76 and last traded at $14.84, with a volume of 743672 shares trading hands. The stock had previously closed at $16.43.

Wall Street Analysts Forecast Growth

KLRA has been the topic of a number of recent analyst reports. Zacks Research upgraded Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. Wall Street Zen downgraded Kailera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Weiss Ratings began coverage on Kailera Therapeutics in a research report on Friday, August 14th. They set a “sell (d)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.75.

Read Our Latest Analysis on Kailera Therapeutics

Kailera Therapeutics Price Performance

The company has a market cap of $1.92 billion and a P/E ratio of -0.00. The business’s fifty day simple moving average is $18.20.

Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). As a group, sell-side analysts predict that Kailera Therapeutics, Inc. will post -3.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Kailera Therapeutics

Large investors have recently modified their holdings of the business. California State Teachers Retirement System purchased a new position in shares of Kailera Therapeutics during the 2nd quarter worth $309,000. Tidal Investments LLC purchased a new position in Kailera Therapeutics during the second quarter worth about $309,000. Squarepoint Ops LLC purchased a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at approximately $993,000. Frazier Life Sciences Management L.P. acquired a new position in shares of Kailera Therapeutics in the 2nd quarter worth approximately $24,233,000. Finally, Wellington Management Group LLP purchased a new position in shares of Kailera Therapeutics during the 2nd quarter worth approximately $64,308,000.

About Kailera Therapeutics

(Get Free Report)

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.